U.S. Markets closed

ADMA Biologics, Inc. (ADMA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.7300+0.0600 (+3.59%)
At close: 4:00PM EDT

1.7400 +0.01 (0.58%)
After hours: 7:55PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.6700
Open1.6125
Bid1.6700 x 1100
Ask1.7300 x 1300
Day's Range1.6101 - 1.7550
52 Week Range1.5700 - 4.2000
Volume3,194,274
Avg. Volume3,793,945
Market Cap212.868M
Beta (5Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Why ADMA Biologics (ADMA) Might Surprise This Earnings Season
    Zacks

    Why ADMA Biologics (ADMA) Might Surprise This Earnings Season

    ADMA Biologics (ADMA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • What Kind Of Investors Own Most Of ADMA Biologics, Inc. (NASDAQ:ADMA)?
    Simply Wall St.

    What Kind Of Investors Own Most Of ADMA Biologics, Inc. (NASDAQ:ADMA)?

    Every investor in ADMA Biologics, Inc. ( NASDAQ:ADMA ) should be aware of the most powerful shareholder groups...

  • ADMA Biologics’ Increased IVIG Production Scale Gets FDA Nod; Shares Gain
    SmarterAnalyst

    ADMA Biologics’ Increased IVIG Production Scale Gets FDA Nod; Shares Gain

    Shares of ADMA Biologics (ADMA) jumped 30% in early trading on Wednesday after the commercial biopharmaceutical company announced that its expanded manufacturing process received US Food and Drug Administration (FDA) approval. The process is designed to enable fractionation and purification of a 4,400-liter plasma pool for the manufacture of Intravenous Immune Globulin (IVIG). ADMA Biologics CEO Adam Grossman said, “The FDA approval of the 4,400-liter IVIG plasma pool production scale process is a transformative milestone for the ADMA organization and will allow the Company to produce significantly more IVIG for the U.S. market and for patients living with immune deficiencies.” “The expanded plasma pool production scale allows us to confidently commit to generating peak revenues in excess of $300 million and this approval solidifies the pathway to meaningful gross margin expansion beginning potentially in the second half of 2021 and accelerating throughout 2022,” Grossman added. (See ADMA Biologics stock analysis on TipRanks) Notably, ADMA’s 4,400-liter IVIG plasma pool scale for BIVIGAM will expand the total processing capacity from 400,000 liters to an expected 600,000 liters. The FDA approval means the company can now produce BIVIGAM at an expanded capacity while maintaining the same high level of quality. Furthermore, the same equipment, release testing assays, disposables, and labor force can also be used. According to the company, significant gross margin improvement is expected as production throughput flows through the standard 7 to 12-month manufacturing cycle for plasma-derived therapies. Additionally, the approval permits ADMA to offer BIVIGAM in both the 50 ml and 100 ml configurations. On April 23, Raymond James analyst Elliot Wilbur reiterated a Buy rating on the stock. Wilbur commented, “ADMA reported 4Q20 results late last month, showing overall positive developments in the challenging plasma market space. The stability of the third-party supplier contract with Grifols remains a clear positive for the company, as inventory continues to grow at rates consistent with the revenue target of $250.0M by 2024. Rapid expansion of ADMA’s collection center portfolio remains a key focus as well, with management having stated that the plasma market supply constraints are not expected to impact the company at this time.” Consensus among analysts is a Strong Buy based on 4 unanimous Buys. The average analyst price target stands at $8.50 and implies upside potential of approximately 255% to current levels. TipRanks’ Stock Investors tool shows that investors currently have a Very Positive stance on ADMA Biologics, with 17.7% of investors increasing their exposure to ADMA stock over the past seven days. Related News: Amazon’s AWS Partners With DISH Network Salesforce Aids Sonos In Digital Transformation Crocs Pops 11% After 1Q Results Beat Expectations More recent articles from Smarter Analyst: Teck Resources 1Q Revenue And Earnings Beat Estimates; Shares Plunge 3% UPS Delivers A Blowout Quarter In 1Q Amgen’s 1Q Results Disappoint; Shares Drop 8% CGI’s Profit Rises To C$341.2M In 2Q